万维提示：
1、该刊只有国际刊号。
2、投稿方式：在线投稿。
3、官网网址（微信公众号信息）：
https://www.the-innovation.org/the-innovation-drug-discovery
4、投稿系统：
https://mc03.manuscriptcentral.com/innovation-drugdisc
5、官网邮箱：drugdiscovery@the-innovation.org
6、出刊日期：季刊，一年出版四期。
7、官方微信公众号：TheInnovation创新
8、官网信息：2027年12月31日前投稿不收文章处理费。
2026年4月23日星期四
For Authors
【官网信息】
Information for Authors
The Innovation Drug Discovery is a joint publication of The Innovation and Chengdu University of Traditional Chinese Medicine. As a sister journal of The Innovation, The Innovation Drug Discovery highlights the most groundbreaking scientific breakthroughs in drug research and development, aiming to bridge the gap in multidisciplinary integration, establish a leading academic platform that promotes global drug discovery and accelerates the development of new therapeutic approaches. The Innovation Drug Discovery aims to become a leading scholarly publication, achieve Zone 1 classification according to the Chinese Academy of Sciences standards, and serve as the premier platform for disseminating pivotal research findings.After publishing, your works will go to global reach and visibility, which is supposed to educate this journal's audience.
The official abbreviation of The Innovation Drug Discovery is "Innov. Drug Discov.".
Aims & Scope
The Innovation Drug Discovery is an international, open-access journal that publishes innovative, rigorous, and impactful research covering the entire drug discovery and development process, as well as content addressing significant themes relevant to the drug discovery and development arena, including but not limited to:
1. Target discovery and validation
2. Rational drug design and drug information
3. Therapeutic targets
4.Small molecules & medicinal chemistry
5. Novel therapeutic strategies
6. Natural products
7. Drug delivery
8. High-throughput screening
9. Preclinical & early phase clinical studies
10. Biopharmaceuticals & large molecules
11. Clinical trials
12. Special drugs
13. AI-assisted de novo drug design
14. Radiopharmaceuticals
Editorial Policies
At The Innovation Drug Discovery, manuscripts are evaluated with the understanding that they have not been previously published in any form, either in print or electronic, and are not under consideration by any other publication or electronic medium. Authors must provide all in-press or submitted works that are relevant to the manuscript under consideration by The Innovation Drug Discovery, including those cited in the manuscript. Additionally, any related manuscripts that have been submitted elsewhere during the revision process must also be included with revised manuscripts. Failure to provide copies of related manuscripts under consideration elsewhere may delay the review process and may be grounds for rejection.
For more information, please visit https://www.the-innovation.org/innovation-press/policies/editorial-policies/.
Preprint servers
The Innovation Drug Discovery welcomes submissions of manuscripts that have previously appeared on recognized preprint servers (e.g., arXiv, bioRxiv, medRxiv). This policy applies only to the original submitted version; authors must not post revisions responding to editorial input or peer review, nor the final published version, on preprint servers. The journal’s prepublication media policy remains applicable to studies shared as preprints. For comprehensive guidelines, please refer to the Innovation Press Self-archiving Policy.
Authorship
Authorship should be based on substantial intellectual contributions to the work, in accordance with ICMJE recommendations. Unrestricted joint first or corresponding authorship is permitted. The corresponding author is responsible for ensuring all co authors have approved the final manuscript and for managing communication with the journal. Detailed criteria, consortia procedures, and authorship change processes are available in the Innovation Press Editorial Policies (Authorship section).
Competing interests
All authors are required to disclose any financial or non financial interests that may constitute a competing interest. A formal "Declaration of Interests" form must be completed prior to acceptance, and a corresponding statement must appear in the manuscript. For further details, please consult the Innovation Press Editorial Policies (Declaration of interests section).
Use of AI-assisted technologies in scientific writing
AI and AI assisted tools may be used solely to improve language and readability, not to replace core researcher responsibilities such as data interpretation or drawing scientific conclusions. AI cannot be listed as an author. Any use of such technologies must be disclosed in a dedicated “Declaration of AI and AI assisted technologies in the writing process” section. Complete disclosure instructions are available in the Innovation Press Open Access Policy (Responsible AI section).
Studies involving humans and animals
Research involving human participants, human derived materials, or animals must adhere to all applicable ethical and regulatory standards. Manuscripts must include statements confirming institutional review board (IRB) or ethics committee approval, informed consent (where applicable), and compliance with animal welfare guidelines. Detailed requirements are provided in the Innovation Press Research Data Policy (Studies involving humans and animals section).
Distribution of materials and data
The Innovation Drug Discovery is committed to open and reproducible research. Authors are expected to make materials, datasets, and code integral to the study available to qualified researchers under minimal restrictions. For guidance on data deposition, repository selection, and data availability statements, please see the Innovation Press Research Data Policy (Distribution of materials and data section).
Plagiarism prevention
All manuscripts submitted to The Innovation Drug Discovery are screened for similarity using iThenticate. Plagiarism, data fabrication, and image manipulation constitute serious violations of publication ethics. Suspected misconduct will be investigated in accordance with COPE guidelines, and consequences may include rejection or retraction. The full detection process and procedures are described in the Innovation Press Research Misconduct Policy.
Editorial Process
All submissions to The Innovation Drug Discovery undergo a thorough evaluation by the scientific editors to determine their suitability for publication. Manuscripts that fail to meet the journal's scope or basic quality standards will be returned to the authors without external review. Otherwise, manuscripts will be sent to at least two reviewers who have agreed in advance to assess the paper rapidly.
Peer review progress
The Innovation Drug Discovery uses a double-blind peer review process, in which the reviewers' identities are not revealed to the authors. The editors make every effort to reach decisions on submitted papers within 3 weeks of the submission date. If revisions are necessary, authors are generally given 4 weeks to make revisions, and only one revised version of the paper is considered. The significance and conceptual advances of each submission are evaluated based on the literature available on the day of final decision, not the day of submission. Accepted papers are published online ahead of the issue as soon as possible and will appear in an issue within 2 months of acceptance. Any major changes to accepted papers are subject to review and may delay publication. The editors and editorial board members are not involved in decisions about papers that they have written themselves, that have been written by family members or colleagues, or that relate to products or services in which the editor has an interest. Any such submission is subject to all of the journal’s usual procedures, with peer review handled independently of the relevant editor and their research groups.
Double-blind peer review protocol
The Innovation Drug Discovery employs a rigorous double blind peer review process. To preserve anonymity, authors are required to submit two separate files: a Title Page (containing author details) and an Anonymized Manuscript (devoid of any identifying information). Complete formatting instructions are available in the Innovation Press Editorial Policies (Double Blind Peer Review Protocol section).
Fast-track review
The Innovation Drug Discovery offers a Fast-track review process for manuscripts requiring urgent attention, in addition to its regular review process. Authors may request this option in their cover letter, and if granted at the editor's discretion, the manuscript will undergo an expedited review with a decision made within 1-3 weeks of submission. The Fast-track process prioritizes manuscripts based on urgency, potential impact, and the availability of suitable reviewers. Our extensive network of expert scientist reviewers and streamlined internal processes provide a solid foundation for prompt peer review discussions, ensuring we maintain high standards of rigor and fairness while achieving rapid turnaround times. We are supported by a large and diverse scientific community, which allows us to quickly identify and engage the most suitable experts for each submission.
While not all manuscripts are eligible for Fast-track review, this option demonstrates our commitment to promptly disseminating crucial findings while upholding the rigorous standards expected in academic publishing. The editor's decision on Fast-track eligibility is final, ensuring that this process is reserved for truly time-sensitive and impactful research.
......
更多详见：
https://www.the-innovation.org/the-innovation-drug-discovery/authors
